Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis

 April 7, 2026

BioSpace

The acquisition of Tubulis GmbH–Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines–brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-st

M&A / DealsRead full story

Post navigation

219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy →
← Gilead outlays $5bn to acquire ADC specialist Tubulis

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com